The differences between the MARCO and SR-A1 structures (By Figdraw).

Download scientific diagram | The differences between the MARCO and SR-A1 structures (By Figdraw). MARCO has a longer collagenous domain and does not have the α-helical coiled-coil domain that is present in SR-A1; MARCO directly binds ligands via the SRCR domain, whereas SR-A1 primarily binds ligands through its collagenous domain from publication: The application of MARCO for immune regulation and treatment | Macrophage receptor with collagen structure (MARCO) is a member of scavenger receptor class A (SR-A) and shares structural and functional similarities with SR-A1. In recent years, many studies have shown that MARCO can trigger an immune response and has therapeutic potential | Immunochemistry, Immunotherapy and B Cells | ResearchGate, the professional network for scientists.

The differences between the MARCO and SR-A1 structures (By Figdraw).

BJNANO - Search Results

Analysis of Macrophage Scavenger Receptor (SR-A) Expression in Human Aortic Atherosclerotic Lesions

Microbiota-mediated shaping of mouse spleen structure and immune function characterized by scRNA-seq and Stereo-seq - ScienceDirect

SIRT3 alleviates high glucose-induced chondrocyte injury through the promotion of autophagy and suppression of apoptosis in osteoarthritis progression - ScienceDirect

Pan-cancer structurome reveals overrepresentation of beta sandwiches and underrepresentation of alpha helical domains

The application of MARCO for immune regulation and treatment

Microbiota-mediated shaping of mouse spleen structure and immune function characterized by scRNA-seq and Stereo-seq - ScienceDirect

Research progress of microglial surface receptors in perioperative neurocognitive disorders - Tang - Ibrain - Wiley Online Library

The huge potential of targeting copper status in the treatment of colorectal cancer

Role of Necroptosis in Central Nervous System Diseases

IJMS, Free Full-Text

Analysis of Macrophage Scavenger Receptor (SR-A) Expression in Human Aortic Atherosclerotic Lesions

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease

A review of the interaction between diet composition and gut microbiota and its impact on associated disease - ScienceDirect